公司资料
Eli Lilly 股价、新闻与催化剂
- 股票代码:
- LLY
- 交易所:
- NYSE
- 行业:
- Biopharma, mRNA Vaccines, Vaccines, Oncology, Small Molecule Drugs
- 所在地:
- United States
股票表现
1,183.16 USD (+0.25%)
收盘价
最后更新: 2026年8月17日
949B USD
市值
股价为何变动
As of Aug 17, 2026, LLY closed up 0.25% at $1183.16. No new same-company headline was identified in the current news window.
公司概览
业务概览
Eli Lilly is a large-cap pharmaceutical company with major exposure to obesity, diabetes, neuroscience, and immunology. The company has become one of the market’s clearest growth stories thanks to its metabolic franchise and broad pipeline.
所在地与行业分类
Headquartered in the United States and listed on NYSE, Lilly is a global pharma company with a strong commercial presence across major markets. Its investor identity is built around growth, execution, and blockbuster product momentum.
商业模式特征
Lilly combines blockbuster product revenue with a deep late-stage pipeline and major manufacturing investment. Investors watch demand, supply expansion, pipeline progress, and whether the company can keep scaling its metabolic and specialty franchises.
生物医药行业定位
Lilly sits at the top tier of large-cap healthcare because it has both scale and strong growth visibility. Compared with smaller biotech names, the stock is less binary but still highly sensitive to launch execution and pipeline durability.
未来催化剂
- Eli Lilly’s next catalysts are still centered on orforglipron, obesity and diabetes filing progress, and retatrutide development and manufacturing readiness. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。